Bristol Myers beat earnings and raised guidance, yet Morgan Stanley kept a $40 target. Here is the patent cliff behind the bank's caution.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results